Bristol Myers Squibb and Pfizer launch direct-to-patient Eliquis program
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/24/2026
- Nasdaq, S&P end lower as tech stocks fall
- Micron posts record profit as AI memory demand fuels explosive growth
- Brent settles at lowest since before start of Iran war as more tankers exit Hormuz
- All eyes on Micron earnings tonight as sell-off raises stakes for AI memory trade
- Alphabet added to Dow Jones Industrial Average, Verizon dropped
- Needham Starts NeoVolta (NEOV) at Buy
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- NextEra to discuss paying about $76 per share for Dominion, Bloomberg News reports
- Campbell Soup (CPB) Declares $0.39 Quarterly Dividend; 7.7% Yield
- UBS Reiterates Buy Rating on Snowflake Inc. (SNOW)
Bristol Myers Squibb and Pfizer Announce Direct-to-Patient Eliquis® (apixaban) Option
July 17, 2025 6:59 AM EDTEliquis 360 Support Program Now Offers Eliquis to Cash-Paying Patients at More than 40% Discount to Current List Price
PRINCETON, N.J.--(BUSINESS WIRE)-- The Bristol Myers Squibb-Pfizer (BMS NYSE: BMY) (Pfizer NYSE: PFE) Alliance today announced a new direct-to-patient option for purchasing Eliquis® (apixaban) via our Alliances patient resource... More
